Zydus Cadila receives final approval for Cyproheptadine Hydrochloride Tablets USP

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Cyproheptadine Hydrochloride Tablets USP, 4 mg. It is an antihistamine used to relieve allergy symptoms such a watery eyes, running nose, itching eyes or nose, sneezing, hives and itching.

The drug will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

Powered by Capital Market - Live News